TECLens Secures Funding for qCXL
TECLens raises $10 Million to advance its non-invasive vision correction platform
1
TECLens secured $10 million in Series A2 extension financing for its quantitative corneal cross-linking (qCXL) platform.
2
The funding will support the expansion of TECLens' first-in-human proof-of-concept program and additional clinical data generation.
3
TECLens' CXLens System reshapes the cornea using personalized ultraviolet light patterns without cutting or removing tissue.
4
The ongoing proof-of-concept study focuses on evaluating qCXL for refractive errors, particularly presbyopia.
5
TECLens will present updates on its clinical development program at the ESCRS meeting and the American Academy of Ophthalmology meeting.
